Diligence memo · auto-generated · as of July 2, 2026
Pharminex, L.L.C.
Pharminex, L.L.C. looks under-valued against its niche peers and is dormant on financing cadence.
Businessfiled
Pharminex, L.L.C. operates in Pharmaceuticals, based in WILLIAMSVILLE.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Pharminex, L.L.C. has raised $12M in disclosed capital across 4 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).
Largest single filing: $4.1M on 2010-12-30.
Most recent recorded round closed around 2012-12-31.
Valuation (modeled)modeled
Provath models Pharminex, L.L.C. at approximately $97M (range $3.6M–$530M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.54× the median modeled value of Series A Pharmaceuticals companies in 2010–2012 (57 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 19 months.
Last raise 13.5 yr ago; this sector typically re-raises about every 13 months.
Silent for over 3× the sector's normal cadence.
The last round stepped up 3.1× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 58% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 54% of those peers.
Closest niche peers: Satori Pharmaceuticals Inc, Labrys Biologics, Inc., Telsar Pharma, Inc., Acetylon Pharmaceuticals, Inc., Seldar Pharma, Inc..
Peoplefiled
6 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.